$BCLI bottom Pr $3.87

New Post Public Reply Private Reply Replies (0) Message Board
PoemStone
$BCLI bottom Pr $3.87


Website

NEW YORK and PETACH TIKVAH, Israel , Oct. 7, 2014 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that the United States Food and Drug Administration (FDA) has designated NurOwn™ as a Fast Track product for the treatment of amyotrophic lateral sclerosis (ALS, or Lou Gehrig's Disease). NurOwn™ consists of autologous mesenchymal stem cells that have been induced to secrete neurotrophic factors, and is currently being studied in a randomized, double-blind, placebo-controlled phase 2 clinical trial in ALS patients.

"We are pleased that the FDA has granted Fast Track status for NurOwn™ as this will allow us greater and more frequent dialogue with the Agency as we continue the development of this ground-breaking cell therapy for the treatment of ALS," said Tony Fiorino , MD, PhD, Chief Executive Officer of BrainStorm. "We expect Fast Track designation, which recognizes the potential of NurOwn™ as to address an unmet medical need in ALS, to help speed and improve our development program."

The FDA's Fast Track program is designed to facilitate the development and expedite the review of drugs and biologics intended to treat serious conditions and demonstrate the potential to address unmet medical needs. Under the FDA Modernization Act of 1997, the Fast Track program provides for increased meetings with and written communications from the FDA, and allows for the submission of an NDA on a rolling basis. For more information, see http://www.fda.gov/ForPatients/Approvals/Fast/ucm405399.htm .

About BrainStorm Cell Therapeutics Inc.

BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn™ technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University . NurOwn™ has been administered to over 30 patients with ALS in clinical trials conducted in Israel , and is currently being studied in a randomized, double-blind, placebo-controlled clinical trial in the United States.

Shares Outstanding: 15.16M
Float: 11.34M




Headlines

Tuesday, October 7, 2014
FDA Grants Fast Track Designation to NurOwn™ for the Treatment of ALSPR Newswire

Monday, October 6, 2014
BrainStorm Reports Last Patient Visit in Phase 2a ALS StudyPR Newswire

Friday, October 3, 2014
BRAINSTORM CELL THERAPEUTICS INC. FinancialsEDGAR Online Financials

Tuesday, September 30, 2014
BrainStorm Completes Uplisting to the NASDAQ Capital MarketMarketwired

Tuesday, September 16, 2014
BRAINSTORM CELL THERAPEUTICS INC. Files SEC form 8-K, Material Modification to Rights of Security Holders, AmendmentsEDGAR Online
BrainStorm Announces Completion of Reverse Split of Common Stock, a Key Step for Uplisting on the NASDAQAccesswire
Tuesday, September 9, 2014
BrainStorm Provides Update on NASDAQ Uplisting ProcessMarketwired

Thursday, September 4, 2014
BrainStorm to Present at the Rodman and Renshaw 16th Annual Global Investment ConferenceAccesswire

Wednesday, September 3, 2014
BrainStorm Granted European Patent Covering its Stem Cells for the Treatment of CNS DiseasesAccesswire

Monday, August 18, 2014
FDA Clears Mayo Clinic for Manufacture of NurOwn and Participation in BrainStorm’s Phase 2 ALS TrialAccesswire

Wednesday, August 13, 2014
BCLI: Brainstorm Moves Into Phase 2 ALS TrialZacks Small Cap Research

Wednesday, July 30, 2014
Coverage initiated on Brainstorm Cell Therapeutics by Maxim GroupBriefing.com

Monday, July 28, 2014
BrainStorm Receives Notice of Allowance on US PatentAccesswire

Tuesday, July 15, 2014
BrainStorm Announces that University of Massachusetts Memorial Medical Center to Begin Enrolling Patients in Phase 2 ALS Clinical TrialAccesswire

Friday, July 11, 2014
BrainStorm Announces Publication of Preclinical Multidose Study of NurOwnMarketwired

Friday, June 27, 2014
BrainStorm Cell, Octane construct bioreactor prototype for NurOwntheflyonthewall.com
BrainStorm and Octane Successfully Construct a Bioreactor Prototype for Industrial-Scale Manufacturing or NurOwn Stem CellsMarketwired

Tuesday, June 24, 2014
Brainstorm Cell Therapeutics, Inc.: A Small Biotech With Big Plans And Huge Potentialat Seeking Alpha

Friday, June 13, 2014
BrainStorm Cell Therapeutics Raises $10.5 Million in Private Placement FinancingMarketwired

Thursday, June 12, 2014
BrainStorm Tackles Neurodegenerative Diseases With Novel Cell Therapyat Seeking Alpha



Featured stocks: Coffee Shoppe
For conservative debate: "Keeping it Real"
Game Changing stock $SHMP

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Countries Eye New Investment Paths at CIFIT 2026

Updated Category News Views 3

Global Investment Winds Shift at CIFIT In the thick of a world that's being turned on its head, you've got big shots from 129 countries and 30 international organizations talking shop at the 26th China International Fair for Investment and Trade (CIFIT) in Xiamen. Take your pick from the 48 of the world's top 50 GDP powerhouses rubbing shoulders there—this ain't your...

Continue Reading
Nocpix Unveils ACE 2 Thermal Riflescope Lineup

Updated Category News Views 3

ACE 2: A Thermal Riflescope That Promises More Let’s dive right into the nitty-gritty of Nocpix’s latest move. On September 12, they launched the ACE 2 Series—the next-gen beast of their flagship thermal riflescope lineup. A step up from the original ACE, this series aims to redefine what hunters can expect from a riflescope, introducing three models: ACE 2 S60R,...

Continue Reading
Silk Road Maritime Extends Its Global Reach in 2026

Updated Category News Views 4

China-Europe Trade Ties Continue to Tighten You ever watch a cargo ship glide into port and think, "There's a piece of the future right there”? Well, that's the scene at Poland’s Gdansk Port, now officially etched into the Silk Road Maritime route. This ain't just a couple of extra boats cutting through choppy waters—it's a great leap forward for a strained global...

Continue Reading
ARTiSTORY's Strategic Advance in Cultural IP Licensing

Updated Category News Views 5

Call it a seismic shift or call it common sense, but ARTiSTORY's recent haul of accolades makes it clear: they're onto something big in the cultural IP game. Receiving four honors at the 26th International Advertising Institute Awards (IAI Awards), including a Gold for their British Library × CHAGEE collaboration, and jumping into License Global's Top 60, they're staking...

Continue Reading
IASLC Boosts Global Thoracic Cancer Collaboration

Updated Category News Views 3

Breaking Down Barriers in Thoracic Oncology Picture a world where financial walls don't block innovation and knowledge sharing in cancer treatment. The International Association for the Study of Lung Cancer (IASLC) is leading the charge here. They've just launched a new initiative offering complimentary full membership to qualified healthcare professionals in low- and...

Continue Reading
SystImmune's Data on Iza-bren Show Promise for Lung Cancer

Updated Category News Views 7

Stepping into New Territory with SystImmune Amid the cacophony of biotech whispers and the marketplace hum, SystImmune is trotting out something that might just make the folks in lab coats raise an eyebrow. They’ve got new data for Iza-bren—none of that flashy PR chatter—but it's damn promising if you ask me. At the World Conference on Lung Cancer in Seoul,...

Continue Reading
PathoSearch: A New Era in Pathology With Visual Search

Updated Category News Views 7

Revolutionizing Pathology with a Visual Search Engine In an era where time is money and precision is paramount, Aignostics is betting big on transforming the pathology landscape. Today, their announcement of PathoSearch, a visual search engine designed for retrieving comparable diagnosed pathology cases, marks a massive leap towards streamlining the diagnostic process....

Continue Reading
Delhi Pushes Innovation Against Dryland Challenges

Updated Category News Views 4

Evolution of South-South Agricultural Cooperation Let's just say if there's a time to shine a spotlight on the arid lands of our world, it's now. The Global Drylands Congress 2026 in New Delhi put a sharp focus on scaling agricultural innovation across these thirsty regions. With climate change breathing down our necks, talking shop about food security isn't just for show...

Continue Reading

Top 5 Most Recently Viewed Articles

Restoration Celebration Highlights Klamath River Project Success

Updated Category News Views 178

Restoration Celebration Highlights Klamath River Project Success The Klamath River has long been a vital natural resource, nurturing ecosystems and communities alike. Recently, a significant milestone was reached with the completion of construction on four priority tributaries, marking an exciting new chapter in environmental restoration. This achievement was celebrated...

Continue Reading
Federal Reserve's New Capital Plan: Impacts on Banking Industry

Updated Category News Views 131

Fed Outlines Changes to Bank Capital Rules The Federal Reserve has rolled out notable revisions to its bank capital framework, a move that’s already stirred debate across the financial world. The updates follow sustained pushback from banks and are intended to change how capital requirements are applied—easing parts of earlier, tougher proposals that drew sharp...

Continue Reading
Jim Walton's Major Stock Transaction: What It Means for Walmart

Updated Category News Views 345

Jim Walton's Notable Walmart Stock Transactions Recently, Jim Walton, one of the main shareholders of Walmart Inc. (NYSE: WMT), made headlines with his significant stock transactions. As per the latest filings, Walton sold an impressive 2,472,613 shares, bringing in around $170.98 million. These sales took place over just a few days, highlighting Walton's strategic method...

Continue Reading
NIIT MTS and Sana Join Forces for Innovative Learning Solutions

Updated Category News Views 162

Strategic Partnership for Enhanced Learning Solutions NIIT Learning Systems Limited (NIIT MTS) has formed a strategic partnership with Sana, a pioneering AI company, to create a Center of Excellence dedicated to transforming learning services. This collaboration aims to redefine how educational content is delivered, leveraging advanced technology to provide organizations...

Continue Reading
Perrigo Initiates Evaluation of Infant Formula Division to Boost Growth

Updated Category News Views 163

Perrigo Initiates Evaluation of Infant Formula Division Perrigo Company plc (NYSE: PRGO), a prominent player in the consumer health sector, has recently declared its intention to commence a strategic evaluation of its infant formula segment. This initiative reflects the company's dedication to exploring various strategic alternatives aimed at strengthening its financial...

Continue Reading